Earnings Releases·Nov 13, 2026, 8:35 AM ET

Xenetic Biosciences — Third Quarter 2026 Earnings Summary

Royalty revenue declined 29% to $0.7 million and net loss widened to $1.7 million ($0.72/share) from $0.5 million ($0.33/share) in the prior year, driven by lower manufacturing costs offset by a 138% increase in G&A expenses due to transaction advisory fees.
The company holds $5.8 million in cash as of September 30, 2026, down from $7.9 million at year-end 2025, while advancing a definitive all-stock share exchange agreement to acquire Santersus AG.
The combined entity, to be named Santersus Bio, Inc. (ticker "SNTS"), expects to close the transaction in Q1 2027 pending regulatory and stockholder approvals, merging Xenetic's DNase platform with Santersus's two FDA Breakthrough Device Designations.
Future catalysts include initial Phase I efficacy data for DNase I with anti-CD19 CAR T-cell therapy in Q2 2027, alongside ongoing pivotal sepsis and lupus studies within the combined pipeline.